Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Sintilimab in Clinical Practice Among Chinese Patients

PD-1 Clinical Trial

Official title:

Clinical Study on Multidimensional Prevention of Sintilimab Induced irAEs Based on GEP Pattern Recognition

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04840355
• Other study ID #: LC2020L03
• Status: Recruiting
• Start date: February 26, 2021
• Est. completion date: October 1, 2024

Study information

• Verified date: April 2021
• Source: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

In recent years, immunotherapy has become one of the important treatments for malignant tumors. Among them, PD-1 inhibitors have been widely used in clinical practice, and have shown a significant survival benefits in many patients. However, the incidence of immune-related adverse reactions (irAEs) of PD-1 inhibitors is relatively high, and severe cases can even threaten patients's life. At present, irAEs have become a bottleneck and it is urgent to establish a prevention strategy for the prediction of irAEs. In this study, we intends to use Sintilimab as the research drug. A prospective cohort study was carried out. Part of the sample which was used as a training set would be detected for producing a time-series multi-dimensional data such as differential genes, metabolites and immune factors. Then gene expression programming (GEP) was used to explore the irAEs recognition model. Then, based on this recognition model, internal verification ( part of samples from the center 1 ) and external verification ( part of samples from the center 2 and center 3 samples) are carried out to accurately predict the high-risk population of irAEs and realize the early-stage warning of Sintilimab induced- irAEs.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: October 1, 2024
• Est. primary completion date: December 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Age =18 and =75 years old;

2. Subjects with histologically or cytologically confirmed are prepared to receive Sintilizumab treatment;

3. Life expectancy of at least 6 months;

4. Eastern Cooperative Oncology Group (ECOG) PS status= 2 or Karnofsky (KPS) = 60;

5. No prior immune checkpoint inhibitor treatment

6. Signed written informed consent before any study-related procedure;

7. Adequate hematopoietic function as defined by an absolute neutrophil count =1.5×109 /L, platelet count=80×109 /L, hemoglobin=90 g/L

8. Adequate hepatic function, defined as a total bilirubin level=1.5 ×upper limit of normal (ULN); aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels =2.5 × ULN in subjects without liver metastases, AST and ALT levels =5 × ULN in subjects with documented liver metastases;

9. Adequate renal function, defined as serum creatinine (Cr)=1.5×ULN or calculated creatinine clearance=60ml/min (Cockcroft-Gault formula);

10. Serum albumin =28g/L;

11. Thyroid-stimulating hormone (TSH)=1×ULN (if abnormal,subject with the normal levels of FT3 and FT4 can be enrolled).

Exclusion Criteria:

1. Has active autoimmune disease;

2. Severe heart, lung, brain, kidney, gastrointestinal or systemic diseases;

3. has interstitial lung disease;

4. Simultaneous use of drugs that can affect the results of this study;

5. Treatment may interfere with the results of the study

6. Allergy or intolerance to the study drug

7. subject with unconsciousness and psychiatric disorder

8. Pregnant and lactating women

9. Subject with poison and alcohol abuse

Related Conditions & MeSH terms

• Immune Related Adverse Events
• PD-1

Intervention

Drug:
• Sintilimab Injection
The recommended dose for intravenous infusion is 200 mg on day 1.Courses repeat every 21 days for up to 6 months in the absence of disease progression or unacceptable toxicity.

Locations

Country	Name	City	State
China	Cancer Hospital Chinese Academy of Medical Sciences	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Guohui Li

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	irAEs	degree of irAEs induced by Sintilimab Injection	24 month